ANI Pharmaceuticals, Inc.. (“ANI”) (Nasdaq: ANIP) today announced the acquisition of Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg from a private company for $3.0 million. The current annual U.S. market for this product is approximately $40 million, according to IQVIA/IMS Health.
Patrick Walsh, ANI’s Interim President and CEO stated, “We are excited to add Fluconazole Tablets, currently manufactured at our site in Oakville, Canada, to our commercial generic portfolio. With this acquisition we further advance our strategy of expanding the ANI product portfolio via the Oakville plant. By leveraging our commercial, manufacturing and packaging capabilities we expect to enhance the margin opportunity and competitive position of this product.”
Source: Biospace